PT-141 dosage forms studied in the published literature tell a story of trial, failure, and reformulation. Unlike many research peptides, which exist in the literature in essentially one presentation, PT-141 (bremelanotide) was investigated in more than one delivery format across its development history — and the format story is inseparable from the compound’s scientific record. This article surveys the PT-141 dosage forms studied strictly as research topics: which formats appeared in published trials, why one program was abandoned, which format carried the compound through Phase III, and how the compound is presented in the research-supply context. There is no dosing guidance here, no administration instructions, and no usage recommendation — the PT-141 dosage forms studied are discussed as objects of research, the way a formulation scientist would discuss them.
Research-use-only disclaimer: This article describes delivery formats as they appear in published research. All products on this site are sold strictly for laboratory research use. Nothing here is medical advice, dosage information, or administration instructions.
PT-141 Dosage Forms Studied: Overview
The published record of PT-141 dosage forms studied centers on two clinical-research formats and one research-supply format. The table below maps them before we examine each in depth.
| Format | Research context | Outcome in the literature |
|---|---|---|
| Intranasal solution | Phase II trials in female sexual dysfunction and male erectile dysfunction | Halted by the FDA in 2007 over blood-pressure signals; development discontinued in 2008 |
| Subcutaneous auto-injector presentation | Phase II dose-finding, then two Phase III RECONNECT trials | Carried the program to FDA approval in June 2019 as Vyleesi |
| Lyophilized (freeze-dried) powder | Standard research-supply presentation for laboratory reference material | Ongoing — the format in which research suppliers provide the compound |
A note on what “studied” means here: when we say these are the PT-141 dosage forms studied, we mean formats that appear in published trials or in the documented research-supply record. The list is descriptive, not prescriptive — it tells you what researchers investigated, not what anyone should use.
The Intranasal Format: Studied, Then Abandoned
The first of the PT-141 dosage forms studied in humans was an intranasal solution. Palatin Technologies ran Phase II trials of intranasal bremelanotide in both female sexual dysfunction and male erectile dysfunction — four trials in ED alone, the last a Phase IIb published in 2008. The nasal route was a deliberate research choice: for peptides generally, intranasal delivery is studied as a non-injectable path, and it is a format researchers keep returning to across the peptide literature (we cover the nasal-spray research context for other compounds in our Selank nasal spray and Semax nasal spray overviews).
The intranasal program’s end is one of the most-cited PT-141 dosage forms studied precisely because it failed. In 2007, the FDA halted the trials after subjects showed increased blood pressure, and Palatin discontinued the intranasal formulation in 2008. The finding that matters for formulation researchers: the cardiovascular signal was tied to the program at that stage, and the response was not to abandon the compound but to abandon the format. Delivery format and compound are separable research questions — a lesson the PT-141 record teaches unusually clearly.
Format profile: Intranasal PT-141
- Studied in: Phase II clinical trials (female sexual dysfunction, male erectile dysfunction)
- Research rationale: non-injectable peptide delivery route under investigation
- Why it ended: FDA halt in 2007 over increased blood pressure in trial subjects
- Research legacy: a case study in format-level risk — the compound survived; the format did not
The Subcutaneous Format: The Path to Approval
The second of the PT-141 dosage forms studied is the subcutaneous presentation delivered via a prefilled auto-injector device — the format of the approved product Vyleesi. After the intranasal program ended, the compound was reformulated for delivery under the skin, and the clinical program restarted in that format. A Phase II dose-finding trial in female sexual dysfunction showed promise at the highest dose tested, with only transient blood-pressure signs, and two Phase III trials were launched at the end of 2014 using the auto-injector presentation.
From a formulation-research perspective, the subcutaneous program is the mirror image of the intranasal one: same active ingredient, different delivery format, different regulatory outcome. The RECONNECT trials — approximately 1,200 participants across two randomized, double-blind, placebo-controlled studies — met their co-primary endpoints on desire and distress, and the FDA approved bremelanotide on June 21, 2019. The published pharmacokinetic literature reports near-complete bioavailability for the subcutaneous route, with maximal levels reached within roughly half an hour to an hour and an elimination half-life of about 2.7 hours. For the compound’s chemistry and trial history, see Wikipedia’s bremelanotide entry and the indexed literature on PubMed.
Format profile: Subcutaneous PT-141 (approved presentation)
- Studied in: Phase II dose-finding and two Phase III RECONNECT trials
- Research rationale: reformulation after the intranasal program’s cardiovascular signals
- Outcome: FDA approval June 21, 2019, as Vyleesi for acquired, generalized HSDD in premenopausal women
- Research legacy: demonstrates that reformulation — not just new chemistry — can rescue a development program
Why researchers compare the two clinical formats: the PT-141 dosage forms studied in trials form a natural controlled comparison — one molecule, two routes, opposite outcomes. That is rare in the peptide literature and is part of why PT-141’s development history gets cited in formulation discussions far beyond its own indication.
The Lyophilized Format: The Research-Supply Standard
The third of the PT-141 dosage forms studied — or more precisely, the format in which the compound is handled as a research subject — is lyophilized (freeze-dried) powder in sealed vials. This is the standard presentation for research peptides generally, and PT-141 is no exception. Lyophilization is a stability strategy: removing water from the peptide slows the hydrolysis of peptide bonds, which is the primary degradation pathway for peptides in solution. The lyophilization process is well documented on Wikipedia for readers unfamiliar with it.
In the research context, lyophilized material is the starting point for laboratory work — analytical characterization, stability studies, receptor-binding assays, and the other bench-level investigations that make up peptide research. Suppliers provide the compound in this format accompanied by testing documentation; the vial is a laboratory reagent, not a medicine, and nothing about its presentation implies otherwise. Our own research listings, such as Semax 10mg and Selank 10mg, follow the same research-supply conventions. The lyophilized format is the least dramatic of the PT-141 dosage forms studied, but it is the one working researchers actually handle.
Format profile: Lyophilized PT-141 (research supply)
- Handled in: laboratory research settings as reference material
- Research rationale: freeze-drying slows peptide-bond hydrolysis, preserving the compound for analysis
- Documentation: typically accompanied by supplier testing documentation (certificate of analysis)
- Research legacy: the unglamorous workhorse format — where bench science actually happens
PT-141 Dosage Forms Studied: Side-by-Side Comparison
Putting the PT-141 dosage forms studied side by side highlights what each format contributed to the scientific record:
| Dimension | Intranasal solution | Subcutaneous auto-injector | Lyophilized powder |
|---|---|---|---|
| Era in the record | Phase II (mid-2000s) | Phase II–III (2010s) | Ongoing research supply |
| Populations studied | Female sexual dysfunction; male erectile dysfunction | Female sexual dysfunction (premenopausal HSDD) | Laboratory research (no human subjects) |
| Key research finding | Blood-pressure signals halted the program | Met Phase III endpoints; approved 2019 | Standard stable presentation for analysis |
| Why it matters to researchers | Format-level risk case study | Reformulation-rescue case study | The format bench work actually uses |
What the literature does not include: the published PT-141 dosage forms studied do not feature an oral tablet program — peptides as a class face well-known absorption barriers by the oral route, and PT-141’s development record simply never went there. Absence from the record is itself a data point: not every format is worth investigating for every compound, and the literature reflects the choices researchers actually made.
What Formulation Researchers Take From the PT-141 Dosage Forms Studied
The PT-141 dosage forms studied are frequently referenced in formulation discussions because they compress several hard-won lessons into one compound’s history. Three stand out.
Lesson 1: The format can fail while the molecule succeeds
The intranasal program’s cardiovascular signals ended a delivery format, not a compound. Researchers who conflate the two risk discarding viable chemistry over a solvable delivery problem.
Lesson 2: Reformulation is a research strategy, not a retreat
Moving from intranasal to subcutaneous delivery was a deliberate scientific response to data — and it produced the program’s only approval. The PT-141 dosage forms studied show reformulation as forward progress.
Lesson 3: The quiet format does the bench work
Lyophilized powder never appears in headlines, but it is the presentation in which characterization, stability, and analytical research actually happen. In the PT-141 dosage forms studied, it is the format researchers touch most.
Taken together, these lessons are why the PT-141 dosage forms studied keep appearing in the literature as more than a historical footnote. They are a compact demonstration that delivery science — route, presentation, device — is a first-class research variable, capable of deciding a compound’s fate independently of its pharmacology. For researchers comparing how different peptides have been presented for study, our Selank vs Semax research comparison applies a similar format-aware lens to two other well-documented compounds.
Key Takeaways — PT-141 Dosage Forms Studied
- The PT-141 dosage forms studied in published research are the intranasal solution (Phase II, discontinued 2008 after an FDA halt over blood-pressure signals), the subcutaneous auto-injector presentation (Phase II–III, approved as Vyleesi in June 2019), and lyophilized powder (the research-supply standard).
- One molecule, two clinical formats, opposite outcomes — the PT-141 record is a textbook case of format-level risk and reformulation rescue.
- Lyophilization is a stability strategy against peptide-bond hydrolysis, and it is the format in which laboratory researchers actually handle the compound.
- No oral program appears in the published record — the literature reflects the formats researchers chose to investigate, nothing more.
- Formats are research topics here, not recommendations. For related format research on other peptides, see our Selank vs Semax research comparison and the nasal-spray overviews linked above.
Conclusion
The PT-141 dosage forms studied across three decades of literature read like a short course in pharmaceutical formulation: an intranasal program that failed on safety signals, a subcutaneous reformulation that carried the same molecule to approval, and a lyophilized research format that keeps the compound available for bench science. Few peptides offer such a clean comparison of what delivery format can and cannot do for a compound’s prospects. For researchers, the PT-141 dosage forms studied are worth knowing not because any format is recommended — none is, here — but because the record shows, in unusual clarity, that in peptide science the vehicle can matter as much as the molecule.
PT-141 Dosage Forms Studied: Frequently Asked Questions
What dosage forms of PT-141 appear in the published research?
Three: an intranasal solution studied in Phase II trials (discontinued in 2008 after an FDA halt over blood-pressure signals), a subcutaneous auto-injector presentation studied in Phase II and Phase III trials (approved as Vyleesi in June 2019), and lyophilized powder, the standard research-supply format for laboratory work.
Why was the intranasal PT-141 format discontinued?
The FDA halted the Phase II intranasal trials in 2007 because subjects showed increased blood pressure. The developer discontinued the intranasal formulation in 2008 and reformulated the compound for subcutaneous delivery.
Which PT-141 dosage form was approved?
The subcutaneous auto-injector presentation — the approved product Vyleesi (bremelanotide), FDA-approved June 21, 2019, for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
What is the lyophilized format used for?
Lyophilized (freeze-dried) powder is the standard presentation for research peptides. Freeze-drying slows hydrolysis of peptide bonds, preserving the compound for laboratory analysis such as characterization and stability studies.
Was an oral PT-141 tablet ever studied?
No oral program appears in the published PT-141 record. The literature covers the intranasal and subcutaneous clinical formats plus the lyophilized research format.
Does this article recommend any dosage form?
No. Formats are discussed strictly as research topics — what the literature covers. The article contains no dosing guidance, no administration instructions, and no usage recommendations. Products on this site are sold for laboratory research use only.
